Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | DUT | P33316 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927440 | 0.81 | HTR7 (0.50) | LMNASMN1; SMN2KDM4EMAPTCYP1A2 | |
| SCHEMBL27094490 | 0.81 | S1PR4 (0.36) | S1PR4POLBMEN1KMT2A | |
| SCHEMBL27094486 | 0.81 | S1PR4 (0.36) | S1PR4POLBMEN1KMT2A | |
| SCHEMBL12134891 | 0.79 | LMNA (0.36) | LMNASMN1; SMN2KDM4EMAPTCYP1A2 | |
| SCHEMBL30542289 | 0.78 | PLCG1 (0.40) | S1PR4LMNASMN1; SMN2KDM4EMAPT | |
| SCHEMBL13139763 | 0.78 | S1PR4 (0.55) | S1PR4LMNASMN1; SMN2KDM4EMAPT | |
| SCHEMBL13552009 | 0.78 | LMNA (0.39) | LMNASMN1; SMN2KDM4EMAPTCYP1A2 | |
| SCHEMBL14092152 | 0.77 | MCHR1 (0.36) | S1PR4POLBMEN1KMT2A | |
| SCHEMBL31362449 | 0.77 | S1PR4 (0.58) | S1PR4LMNASMN1; SMN2KDM4EMAPT | |
| SCHEMBL1725556 | 0.77 | S1PR4 (0.38) | S1PR4DUTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-8835439-B2 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases | PROXIMAGEN LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | BIOVITRUM AB (PUBL) (SE) | 2013-06-20 | — | — | US | disclosed |
| US-8410113-B2 | (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof | BIOVITRUM AB (PUBL) (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-12 | — | — | US | disclosed |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-05 | — | — | US | disclosed |
| US-8030316-B2 | Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine | BIOVITRUM AB (PUBL) (SE) | 2011-10-04 | — | — | US | disclosed |
| US-7820677-B2 | Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20100256374-A1 | NOVEL PROCESS | BIOVITRUM AB, A SWEDEN CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| EP-1645558-A1 | Piperazinylpyrazines as serotonin 5-HT2C receptor modulators | BIOVITRUM AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| EP-1529043-A1 | NOVEL PROCESS | Biovitrum AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040038981-A1 | Novel Process | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-26 | — | — | US | disclosed |
| WO-2004000829-A1 | NOVEL PROCESS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | S1PR4 849/4885LMNA 2553/4885SMN1; SMN2 988/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | S1PR4 919/4885LMNA 2654/4885SMN1; SMN2 997/4885 |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | SUCNR1, HTR5A, HTR2C | S1PR4 746/4885LMNA 4213/4885SMN1; SMN2 767/4885 |
| US-20100256374-A1 | NOVEL PROCESS | HTR1A, TPH1, HTR5A | S1PR4 626/4885LMNA 3746/4885SMN1; SMN2 1537/4885 |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | HTR2C, HTR5A, HTR2A | S1PR4 756/4885LMNA 4207/4885SMN1; SMN2 1536/4885 |
| US-20040038981-A1 | Novel Process | HTR1A, TPH1, HTR1B | S1PR4 506/4885LMNA 4181/4885SMN1; SMN2 1631/4885 |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | S1PR4 756/4885LMNA 4207/4885SMN1; SMN2 1536/4885 |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | S1PR4 756/4885LMNA 4207/4885SMN1; SMN2 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.